Edition 7 – Benefit-Risk at a time of COVID-19 and Brexit

Posted on: Thursday 12 November 2020

Autumn/Winter 2020 edition

Lead Article

Vaccines Safety During Accelerated Research and Development

By Penny Ward FFPM

In a public health emergency, the urgent need for an effective vaccine must be balanced against potential for vaccine related harms to ensure appropriate use. How can this be achieved when developing a vaccine at ‘warp speed’?

Read more

Laboratory

Contents

Principles of benefit-risk assessment: A focus on some practical applications

QP or Not QP – That is the UK post-Brexit question

The Potential of Artificial Intelligence in Pharmacovigilance

Vaccines Safety During Accelerated Research and Development

How has the delivery of safe and effective COVID vaccines been achieved at ‘warp speed’?

Hydroxychloroquine history and its cardiovascular safety

Ethical reflections and the changing world in which we live!

Editions of the JFPM

Edition 7 – Benefit-Risk at a time of COVID-19 and Brexit

Featuring articles from Penny Ward, Saad Shakir, Alastair Benbow and many more.

Edition 6 – Celebrating the ‘WHO Year of the Nurse and Midwife’

Celebrating the ‘WHO Year of the Nurse and Midwife’ through their role in pharma, plus more news and reflections

Edition 5 – 30th Anniversary Special

Looking at the past and to the future of pharmaceutical medicine.

Special Edition – FPM Education Day 2019

Download this meeting report as a PDF (1.8MB).

Edition 4 – Digital Health

Download this edition as a PDF (1MB)

Edition 3 – Paediatric Medicines Development

Download this edition as a PDF (2MB).

Edition 2 – Hot topics in Pharmaceutical Medicine

Download this edition as a PDF (2MB)

Edition 1 – Inaugural Edition

Download this edition as a PDF (508KB)